Fínsko - fínčina - Fimea (Suomen lääkevirasto)

opella healthcare france sas - hyoscine butylbromide - injektioneste, liuos - 20 mg/ml - butyyliskopolamiini

Fínsko - fínčina - Fimea (Suomen lääkevirasto)

sanofi oy - hyoscini butylbromidum - tabletti, päällystetty - 10 mg - butyyliskopolamiini

Fínsko - fínčina - Fimea (Suomen lääkevirasto)

photocure asa - hexaminolevulinate hydrochloridum - jauhe ja liuotin liuosta varten, virtsarakkoon - 85 mg - heksaminolevulinaatti

Fínsko - fínčina - Fimea (Suomen lääkevirasto)

vetviva richter gmbh - ketoprofen - injektioneste, liuos - 100 mg/ml - ketoprofeeni

Fínsko - fínčina - Fimea (Suomen lääkevirasto)

viatris oy - betahistine dihydrochloride - tabletti, suussa hajoava - 24 mg - betahistiini

Fínsko - fínčina - Fimea (Suomen lääkevirasto)

huvepharma nv - eimeria necatrix, strain mednec 3+8, eimeria brunetti, strain roybru 3+28 - suspensio oraalisuspensiota varten - kokkidirokote

Fínsko - fínčina - Fimea (Suomen lääkevirasto)

santen oy - fluorescein sodium, oxybuprocaine hydrochloride - silmätipat, liuos - 1.25 mg/ml + 3 mg/ml - fluoreseiini

Fínsko - fínčina - Fimea (Suomen lääkevirasto)

bayer oy - pyridoxini hydrochloridum,riboflavini natrii phosphas,cyanocobalaminum,nicotinamidum,calcii pantothenas,thiamini monophosphas chloridum dihydricum,calcii carbonas,magnesii sulfas dihydricus,acidum folicum,magnesii subcarbonas ponderosus,zinci citras trihydricus,biotinum,acidum ascorbicum - poretabletti - b-vitamiinien muut yhdistelmävalmisteet

Fínsko - fínčina - Fimea (Suomen lääkevirasto)

krka, d.d., novo mesto- locna - dexpanthenol, xylometazoline hydrochloride - nenäsumute, liuos - 1 mg/ml + 50 mg/ml - ksylometatsoliini

Európska únia - fínčina - EMA (European Medicines Agency)

biontech manufacturing gmbh - single-stranded, 5’-capped messenger rna produced using a cell-free in vitro transcription from the corresponding dna templates, encoding the viral spike (s) protein of sars-cov-2 - covid-19 virus infection - rokotteet - comirnaty 30 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older.  comirnaty 30 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older.  comirnaty 10 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years.  comirnaty 3 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years.  comirnaty original/omicron ba. 1 (15/15 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older who have previously received at least a primary vaccination course against covid-19. comirnaty original/omicron ba. 4-5 (15/15 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older. comirnaty original/omicron ba. 4-5 (5/5 micrograms)/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty original/omicron ba. 4-5 (5/5 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years.  comirnaty original/omicron ba. 4-5 (1. 5/1. 5 micrograms)/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years.  comirnaty omicron xbb. 5 30 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older. comirnaty omicron xbb. 5 10 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty omicron xbb. 5 10 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty omicron xbb. 5 3 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years. käyttö tämä rokote tulee virallisten suositusten mukaisesti.